

## Memo

**Date:** 3 November 2022

**Title:** **Changes to REB Review Fees for Industry-Sponsored Trials**

**Distribution:** OHRI Investigators and Clinical Research Staff

**Effective Date:** 1 January 2023

The OHSN-REB will be implementing an **increase to the initial review fee from \$3000 to \$3500 for new industry-sponsored studies received as of 1 January 2023**. In addition, we will also be implementing a fee for major amendments for new industry-sponsored studies. Study teams should include these new fees in contract negotiations.

The amendment review fee will apply to **major amendments** for studies meeting one of the following criteria:

- ✓ Industry-sponsored studies **or** when industry is contractually receiving data/publication rights and/or access to records
- or**
- ✓ Government agency (i.e., CDC/PHAC/Health Canada etc.) initiated studies which are not peer-reviewed / investigator-initiated, unless by the sole discretion of the REB, the main purpose of such Government agency research is directed to the benefit of public health generally

### What is considered a “major” amendment?

- ✓ Changes to the study design and/or documents that impact the assessment of potential risks to participants.
- ✓ The REB may also classify an amendment as major based on the level of review required to approve the amendment.

### How much is the fee?

- ✓ **\$500** for **major amendments** submitted for studies meeting one of the fee criteria outlined above.
- ✓ **\$2500** for **major amendments** submitted for **adaptive, basket, umbrella and platform trials** meeting one of the fee criteria outlined above **when the amendment involves the addition of new protocols, drugs, consent forms and/or other substantive changes**.

### How do I pay the review fee?

- ✓ Similar to the initial and continuing review fee processes, the amendment fee will be automatically charged to the investigator's project cost centre upon completion of amendment review.
- ✓ Investigators are responsible for invoicing the company for ethics review fees and will manage the collection and payment process.

If you have any questions or concerns, please contact [REBAdministration@ohri.ca](mailto:REBAdministration@ohri.ca).

Thank you,

Penny Phillips  
Director, Clinical Research Administration